Dr. Wolfgang G. Kreyling
External Scientific Advisor

Phone: n/a

Dr. Kreyling is a biophysicist freshly and mandatorily retired from coordinating all aerosol-related research within the Focus Network Nanoparticles and Health of the Helmholtz Zentrum München (HMGU) spanning R&D work over five HMGU-institutes ranging from material sciences to toxicology and epidemiology. He additionally had chaired the R&D program of the HMGU Comprehensive Pneumology Center, Institute of Lung Biology and Disease on dosimetry of ultrafine aerosol particles and engineered nanoparticles in the respiratory tract and secondary target organs like the cardiovascular and the central nervous system.

The research interests of Wolfgang Kreyling range from aerosol sciences and nanoparticle technology to biophysics of the lungs reaching from the characterization of ambient aerosols to particle dosimetry and nanoparticle lung interactions on the level of the entire organism, cells like alveolar macrophages, and molecular compounds. His major early achievements include quantitative analyses of the biokinetics after inhalation of taylor-made physico-chemically uniform, radio-labeled micron-sized particles (0.3 – 5 µm) in six experimental animal species and in humans. The results of these interspecies comparisons were rather influential on the “Human Respiratory Tract Model” of the International Commission for Radiological Protection (ICRP66). In the early 90ies he became interested in ultrafine particles, particularly in ambient urban air and he supervised continuous ambient aerosol measurements in Erfurt and later in Augsburg to be used for exposure estimates for the ongoing epidemiologic studies of the Institute of Epidemiology on the effects of the ultrafine number concentration fraction versus PM2.5 and PM10 mass fractions. More recently he adopted and applied his biokinetics methodology to study the quantitative biokinetics of engineered nanoparticles in rodent models after lung inhalation or instillation as well as after intravenous injection and oral administration. He found that nanoparticles are able to cross cellular and organ membranes to a small but detectable amount depending on their physic-chemical properties having access to blood circulation and leading to subsequent accumulation in secondary organs and tissues including the skeleton. In particular, the smaller the particles are the higher the translocated fraction across organ membranes; hence, micron-sized particles don’t show any detectable translocation across organ membranes.

He spent a sabbatical year in 1985/86 at the Respiratory Biology Program of the Harvard School of Public Health, Boston, USA, and continues this collaboration since then (NIH grant 2003-08; etc.). Since 1999 he coordinated toxicological collaborations between US-EPA NHEERL and HMGU on ambient air pollution research. He and his team currently participated in six EU-FP7 funded projects and two German Research Foundation (DFG) funded consortia on interactions of engineered nanoparticles with biological systems and the safe and sustainable use of nanoparticles.

In recent years Dr. Kreyling held various officer positions within the board of the International Society for Aerosols in Medicine (ISAM) and was its President (2003-2005). He is member of various other international scientific societies (ERS, ATS, EAC, AAAR, GAeF), serves as a member of several expert panels of International (WHO, HEI), European (ESF, EU-DG SANCO, EFSA, ERS, EASAC) and German committees (DFG, BMBF, BMU). He has published 200 peer reviewed articles and book chapters and he is editorial board member of several international aerosol and nanotechnology related journals and he is currently associated editor of Particle & Fibre Toxicology and Toxicology Research.